MedTrace Logo

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

NCT00679939 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2018-04-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosiglitazone

up to 8mg/day

DRUG

Metformin

up to 2000mg/day

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-21
Primary Completion
2010-09-16
Completion
2010-09-16

Countries

  • United States
  • Argentina
  • Canada
  • Estonia
  • Mexico
  • Pakistan
  • Philippines
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679939 on ClinicalTrials.gov